お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:脳腫瘍診断および治療の世界市場:種類別(診断、治療薬)の市場調査、予測(~2025年)、COVID-19の累積的な影響
市場調査レポート
商品コード
1001136

脳腫瘍診断および治療の世界市場:種類別(診断、治療薬)の市場調査、予測(~2025年)、COVID-19の累積的な影響

Brain Tumor Diagnosis & Therapeutics Market Research Report by Type (Diagnosis and Therapeutics) - Global Forecast to 2025 - Cumulative Impact of COVID-19

出版日: | 発行: 360iResearch LLP | ページ情報: 英文 196 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.15円
脳腫瘍診断および治療の世界市場:種類別(診断、治療薬)の市場調査、予測(~2025年)、COVID-19の累積的な影響
出版日: 2021年04月15日
発行: 360iResearch LLP
ページ情報: 英文 196 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の脳腫瘍診断および治療の市場規模は、2020年の12億6,091万米ドルから、2025年末までに18億8,273米ドルに成長すると予想されています。

市場セグメンテーションとカバレッジ

この調査レポートは、脳腫瘍診断および治療の世界市場を分類して、収益を予測し、次の各サブマーケットの動向を分析します。

  • 種類別では、市場は、診断と治療に渡り調査されました。診断セグメントは、脳動脈造影、CTスキャン、EEG、腰椎穿刺、分子検査、MRI、PET-CTスキャン、および組織サンプリングに渡り更に調査されました。治療セグメントは、化学療法、免疫療法、放射線療法、外科手術、および標的療法に渡り更に調査されました。
  • 地域別では、市場は、南北アメリカ、アジア太平洋、および欧州と中東・アフリカに分けて調査されました。南北アメリカ地域はアルゼンチン、ブラジル、カナダ、メキシコ、および米国。アジア太平洋地域はオーストラリア、中国、インド、インドネシア、日本、マレーシア、フィリピン、韓国、タイ。欧州と中東およびアフリカ地域は、フランス、ドイツ、イタリア、オランダ、カタール、ロシア、サウジアラビア、南アフリカ、スペイン、アラブ首長国連邦、および英国において調査されました。南北アメリカは2020年に脳腫瘍診断および治療の市場で最大の規模を占めました。一方、アジア太平洋地域は予測期間中に最速のCAGRで成長すると予想されます。

企業のユーザビリティプロファイル

当レポートはAmgen Inc.、AstraZeneca PLC、Bayer AG、Bristol-Myers Squibb Co、Carestream Health, Inc.、Eisai Inc.、F. Hoffmann-La Roche Ltd、Fujifilm Corporation、GE Healthcare Inc.、GlaxoSmithKline PLC、Hitachi, Ltd.、Johnson & Johnson、Merck & Co. Inc.、Novartis AG、Pfizer, Inc.、Philips Healthcare、S&P Global Inc.、Shimadzu Corporation、Siemens Healthineers AG、Toshiba Corporation、Toshiba Medical Systemsなど、世界市場における主要ベンダーによる最近の重要な進展とイノベーションプロファイルを深く探求しています。

COVID-19の累積的影響

COVID-19は、ほぼすべての業界に影響を与えた比類のない世界的な公衆衛生上の緊急事態であるため、予測期間中に業界の成長に長期的な影響を与えると予測されます。私たちの進行中の調査は、調査フレームワークを増幅して、基礎となるCOVID-19の問題と今後の潜在的な道筋を確実に含めるようにしています。調査は消費者の行動と需要の変化、購入パターン、サプライチェーンの再ルーティング、現在の市場の力のダイナミクス、および政府の重要な介入を考慮した、COVID-19に関する洞察を提供しています。更新された調査は、市場へのCOVID-19の影響を考慮して、洞察、分析、推定、および予測を提供します。

 

当レポートでは脳腫瘍診断および治療の世界市場を調査し、市場の概要、市場の成長要因および阻害要因の分析、市場機会、COVID-19の影響、種類別・地域別の市場規模の推移と予測、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

360iResearch(TM)FPNVポジショニングマトリックス

360iResearch(TM)FPNVポジショニングマトリックスは、企業がより良い意思決定を行い、競合情勢を理解するのに役立つビジネス戦略(ビジネスの成長、業界のカバレッジ、経済的実行可能性、チャネルサポート)と製品の満足度(コストパフォーマンス、使いやすさ、製品の機能、およびカスタマーサポート)に基づいて、当市場のベンダーを評価および分類します。

360iResearch(TM)コンペティティブ・ストラテジック・ウィンドウ(競争力のある戦略的ウィンドウ):

360iResearch(TM)コンペティティブ・ストラテジック・ウィンドウは、市場、アプリケーション、および地域の観点から競合情勢を分析します。 これはベンダーが将来の成長見通しに対する能力と機会の間の調整または適合を定義するのに役立ちます。予測期間中に、ベンダーが継続的な合併および買収戦略、地域の拡大、研究開発、および新製品の導入戦略を採用して、さらなる事業の拡大と成長を実行するための最適または有利な適合を定義します。

目次

第1章 序文

  • 調査の目的
  • 市場セグメンテーションとカバレッジ
  • 調査のために考慮された年
  • 通貨と価格
  • 言語
  • 制限事項
  • 利害関係者

第2章 調査手法

  • 調査プロセス
    • 定義:調査目的
    • 決定:調査デザイン
    • 準備:調査機器
    • 収集:データソース
    • 分析:データの解釈
    • 策定:データ検証
    • 公開:調査レポート
    • 繰り返し:レポートの更新
  • 調査の実行
    • 開始:調査プロセス
    • 計画:調査計画の作成
    • 実行:調査の実施
    • 検証:発見と分析
    • 出版物:調査報告
  • 調査成果

第3章 エグゼクティブサマリー

  • 市場の見通し
  • 種類の見通し
  • 地域の見通し
  • 競合他社の見通し

第4章 市場概要

  • COVID-19の累積的影響

第5章 市場の洞察

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題
  • ポーターズのファイブフォース分析
    • 新規参入業者の脅威
    • 代替品の脅威
    • 顧客の交渉力
    • 供給企業の交渉力
    • 業界の競争

第6章 種類別

  • 診断
    • 脳動脈造影
    • CTスキャン
    • EEG
    • 腰椎穿刺
    • 分子検査
    • MRI
    • PET-CTスキャン
    • 組織サンプリング
  • 治療
    • 化学療法
    • 免疫療法
    • 放射線治療
    • 手術
    • 標的療法

第7章 南北アメリカ

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第8章 アジア太平洋地域

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • 韓国
  • タイ

第9章 欧州、中東・アフリカ

  • フランス
  • ドイツ
  • イタリア
  • オランダ
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • アラブ首長国連邦
  • 英国

第10章 競合情勢

  • FPNVポジショニングマトリックス
    • 象限
    • 事業戦略
    • 製品の満足度
  • 市場ランキング分析
  • 市場シェア分析
  • 競合他社のSWOT分析
  • 競合シナリオ
    • 合併と買収
    • 合意、コラボレーション、およびパートナーシップ
    • 新製品の発売と強化
    • 投資と資金調達
    • 賞、表彰、拡大

第11章 企業のユーザビリティプロファイル

  • Amgen Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol-Myers Squibb Co
  • Carestream Health, Inc.
  • Eisai Inc.
  • F. Hoffmann-La Roche Ltd
  • Fujifilm Corporation
  • GE Healthcare Inc.
  • GlaxoSmithKline PLC
  • Hitachi, Ltd.
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Philips Healthcare
  • S&P Global Inc.
  • Shimadzu Corporation
  • Siemens Healthineers AG
  • Toshiba Corporation
  • Toshiba Medical Systems

第12章 付録

  • ディスカッションガイド
  • ライセンスと価格
図表

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: RESEARCH PROCESS
  • FIGURE 2. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: RESEARCH EXECUTION
  • FIGURE 3. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, 2020 VS 2025 (USD MILLION)
  • FIGURE 4. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2020 (USD MILLION)
  • FIGURE 5. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
  • FIGURE 6. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, 2018-2025 (USD MILLION)
  • FIGURE 7. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: MARKET DYNAMICS
  • FIGURE 8. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: PORTERS FIVE FORCES ANALYSIS
  • FIGURE 9. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2020 VS 2025 (%)
  • FIGURE 10. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2020 VS 2025 (USD MILLION)
  • FIGURE 11. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2025
  • FIGURE 12. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, 2020 VS 2025 (USD MILLION)
  • FIGURE 13. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CEREBRAL ARTERIOGRAM, 2020 VS 2025 (USD MILLION)
  • FIGURE 14. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CT SCAN, 2020 VS 2025 (USD MILLION)
  • FIGURE 15. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY EEG, 2020 VS 2025 (USD MILLION)
  • FIGURE 16. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY LUMBAR PUNCTURE, 2020 VS 2025 (USD MILLION)
  • FIGURE 17. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR TESTING, 2020 VS 2025 (USD MILLION)
  • FIGURE 18. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MRI, 2020 VS 2025 (USD MILLION)
  • FIGURE 19. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PET-CT SCAN, 2020 VS 2025 (USD MILLION)
  • FIGURE 20. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TISSUE SAMPLING, 2020 VS 2025 (USD MILLION)
  • FIGURE 21. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2020 VS 2025 (USD MILLION)
  • FIGURE 22. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, 2020 VS 2025 (USD MILLION)
  • FIGURE 23. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, 2020 VS 2025 (USD MILLION)
  • FIGURE 24. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, 2020 VS 2025 (USD MILLION)
  • FIGURE 25. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, 2020 VS 2025 (USD MILLION)
  • FIGURE 26. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2020 VS 2025 (USD MILLION)
  • FIGURE 27. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 28. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 29. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 30. ARGENTINA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 31. BRAZIL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 32. CANADA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 33. MEXICO BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 34. UNITED STATES BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 35. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 36. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 37. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 38. AUSTRALIA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 39. CHINA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 40. INDIA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 41. INDONESIA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 42. JAPAN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 43. MALAYSIA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 44. PHILIPPINES BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 45. SOUTH KOREA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 46. THAILAND BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 47. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
  • FIGURE 48. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
  • FIGURE 49. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2025
  • FIGURE 50. FRANCE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 51. GERMANY BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 52. ITALY BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 53. NETHERLANDS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 54. QATAR BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 55. RUSSIA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 56. SAUDI ARABIA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 57. SOUTH AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 58. SPAIN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 59. UNITED ARAB EMIRATES BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 60. UNITED KINGDOM BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
  • FIGURE 61. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: FPNV POSITIONING MATRIX
  • FIGURE 62. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: MARKET SHARE ANALYSIS
  • FIGURE 63. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: COMPETITOR SWOT ANALYSIS
  • FIGURE 64. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET, BY TYPE

LIST OF TABLES

  • TABLE 1. CURRENCY CONVERSION RATES
  • TABLE 2. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 3. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 4. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 5. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CEREBRAL ARTERIOGRAM, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 6. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CT SCAN, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 7. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY EEG, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 8. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY LUMBAR PUNCTURE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 9. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MOLECULAR TESTING, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 10. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY MRI, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 11. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY PET-CT SCAN, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 12. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TISSUE SAMPLING, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 13. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 14. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 15. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY IMMUNOTHERAPY, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 16. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY RADIATION THERAPY, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 17. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY SURGERY, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 18. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 19. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 20. AMERICAS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 21. ARGENTINA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 22. BRAZIL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 23. CANADA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 24. MEXICO BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 25. UNITED STATES BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 26. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 27. ASIA-PACIFIC BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 28. AUSTRALIA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 29. CHINA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 30. INDIA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 31. INDONESIA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 32. JAPAN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 33. MALAYSIA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 34. PHILIPPINES BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 35. SOUTH KOREA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 36. THAILAND BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 37. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 38. EUROPE, MIDDLE EAST & AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 39. FRANCE BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 40. GERMANY BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 41. ITALY BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 42. NETHERLANDS BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 43. QATAR BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 44. RUSSIA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 45. SAUDI ARABIA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 46. SOUTH AFRICA BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 47. SPAIN BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 48. UNITED ARAB EMIRATES BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 49. UNITED KINGDOM BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
  • TABLE 50. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: SCORES
  • TABLE 51. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: BUSINESS STRATEGY
  • TABLE 52. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: PRODUCT SATISFACTION
  • TABLE 53. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: RANKING
  • TABLE 54. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: MERGER & ACQUISITION
  • TABLE 55. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
  • TABLE 56. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
  • TABLE 57. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: INVESTMENT & FUNDING
  • TABLE 58. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: AWARD, RECOGNITION, & EXPANSION
  • TABLE 59. GLOBAL BRAIN TUMOR DIAGNOSIS & THERAPEUTICS MARKET: LICENSE & PRICING
目次
Product Code: MRR-905E62D

Market Statistics

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.

  • 1. The Global Brain Tumor Diagnosis & Therapeutics Market is expected to grow from USD 1,260.91 Million in 2020 to USD 1,882.73 Million by the end of 2025.
  • 2. The Global Brain Tumor Diagnosis & Therapeutics Market is expected to grow from EUR 1,105.58 Million in 2020 to EUR 1,650.81 Million by the end of 2025.
  • 3. The Global Brain Tumor Diagnosis & Therapeutics Market is expected to grow from GBP 982.87 Million in 2020 to GBP 1,467.57 Million by the end of 2025.
  • 4. The Global Brain Tumor Diagnosis & Therapeutics Market is expected to grow from JPY 134,571.04 Million in 2020 to JPY 200,934.99 Million by the end of 2025.
  • 5. The Global Brain Tumor Diagnosis & Therapeutics Market is expected to grow from AUD 1,831.00 Million in 2020 to AUD 2,733.97 Million by the end of 2025.

Market Segmentation & Coverage

This research report categorizes the Brain Tumor Diagnosis & Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:

  • Based on Type, the Brain Tumor Diagnosis & Therapeutics Market studied across Diagnosis and Therapeutics. The Diagnosis further studied across Cerebral Arteriogram, CT Scan, EEG, Lumbar Puncture, Molecular Testing, MRI, PET-CT Scan, and Tissue Sampling. The Therapeutics further studied across Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and Targeted Therapy.

"The Asia-Pacific is projected to witness the highest growth during the forecast period"

  • Based on Geography, the Brain Tumor Diagnosis & Therapeutics Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. The Americas commanded the largest size in the Brain Tumor Diagnosis & Therapeutics Market in 2020. On the other hand, the Asia-Pacific is expected to grow at the fastest CAGR during the forecast period.

Company Usability Profiles

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Brain Tumor Diagnosis & Therapeutics Market including Amgen Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Co, Carestream Health, Inc., Eisai Inc., F. Hoffmann-La Roche Ltd, Fujifilm Corporation, GE Healthcare Inc., GlaxoSmithKline PLC, Hitachi, Ltd., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer, Inc., Philips Healthcare, S&P Global Inc., Shimadzu Corporation, Siemens Healthineers AG, Toshiba Corporation, and Toshiba Medical Systems.

Cumulative Impact of COVID-19

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

360iResearch™FPNV Positioning Matrix

The 360iResearch™ FPNV Positioning Matrix evaluates and categorizes the vendors in the Brain Tumor Diagnosis & Therapeutics Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

360iResearch™Competitive Strategic Window

The 360iResearch™ Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch™ Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

The report provides insights on the following pointers:

  • 1. Market Penetration: Provides comprehensive information on the market offered by the key players
  • 2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
  • 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
  • 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
  • 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

  • 1. What is the market size and forecast of the Global Brain Tumor Diagnosis & Therapeutics Market?
  • 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Brain Tumor Diagnosis & Therapeutics Market during the forecast period?
  • 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Brain Tumor Diagnosis & Therapeutics Market?
  • 4. What is the competitive strategic window for opportunities in the Global Brain Tumor Diagnosis & Therapeutics Market?
  • 5. What are the technology trends and regulatory frameworks in the Global Brain Tumor Diagnosis & Therapeutics Market?
  • 6. What are the modes and strategic moves considered suitable for entering the Global Brain Tumor Diagnosis & Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Stakeholders

2. Research Methodology

  • 2.1. Research Process
    • 2.1.1. Define: Research Objective
    • 2.1.2. Determine: Research Design
    • 2.1.3. Prepare: Research Instrument
    • 2.1.4. Collect: Data Source
    • 2.1.5. Analyze: Data Interpretation
    • 2.1.6. Formulate: Data Verification
    • 2.1.7. Publish: Research Report
    • 2.1.8. Repeat: Report Update
  • 2.2. Research Execution
    • 2.2.1. Initiation: Research Process
    • 2.2.2. Planning: Develop Research Plan
    • 2.2.3. Execution: Conduct Research
    • 2.2.4. Verification: Finding & Analysis
    • 2.2.5. Publication: Research Report
  • 2.3. Research Outcome

3. Executive Summary

  • 3.1. Introduction
  • 3.2. Market Outlook
  • 3.3. Type Outlook
  • 3.4. Geography Outlook
  • 3.5. Competitor Outlook

4. Market Overview

  • 4.1. Introduction
  • 4.2. Cumulative Impact of COVID-19

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of neurological disorders
      • 5.1.1.2. Need for tests detecting the presence of tumors
      • 5.1.1.3. Research activities in the molecular diagnostics
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the diagnosis and treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising healthcare expenditure and the favorable reimbursement policies
      • 5.1.3.2. Growing healthcare awareness about the management and therapies of brain tumor
      • 5.1.3.3. Government initiatives for cancer awareness
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with brain tumor therapeutics
  • 5.2. Porters Five Forces Analysis
    • 5.2.1. Threat of New Entrants
    • 5.2.2. Threat of Substitutes
    • 5.2.3. Bargaining Power of Customers
    • 5.2.4. Bargaining Power of Suppliers
    • 5.2.5. Industry Rivalry

6. Global Brain Tumor Diagnosis & Therapeutics Market, By Type

  • 6.1. Introduction
  • 6.2. Diagnosis
    • 6.2.1. Cerebral Arteriogram
    • 6.2.2. CT Scan
    • 6.2.3. EEG
    • 6.2.4. Lumbar Puncture
    • 6.2.5. Molecular Testing
    • 6.2.6. MRI
    • 6.2.7. PET-CT Scan
    • 6.2.8. Tissue Sampling
  • 6.3. Therapeutics
    • 6.3.1. Chemotherapy
    • 6.3.2. Immunotherapy
    • 6.3.3. Radiation Therapy
    • 6.3.4. Surgery
    • 6.3.5. Targeted Therapy

7. Americas Brain Tumor Diagnosis & Therapeutics Market

  • 7.1. Introduction
  • 7.2. Argentina
  • 7.3. Brazil
  • 7.4. Canada
  • 7.5. Mexico
  • 7.6. United States

8. Asia-Pacific Brain Tumor Diagnosis & Therapeutics Market

  • 8.1. Introduction
  • 8.2. Australia
  • 8.3. China
  • 8.4. India
  • 8.5. Indonesia
  • 8.6. Japan
  • 8.7. Malaysia
  • 8.8. Philippines
  • 8.9. South Korea
  • 8.10. Thailand

9. Europe, Middle East & Africa Brain Tumor Diagnosis & Therapeutics Market

  • 9.1. Introduction
  • 9.2. France
  • 9.3. Germany
  • 9.4. Italy
  • 9.5. Netherlands
  • 9.6. Qatar
  • 9.7. Russia
  • 9.8. Saudi Arabia
  • 9.9. South Africa
  • 9.10. Spain
  • 9.11. United Arab Emirates
  • 9.12. United Kingdom

10. Competitive Landscape

  • 10.1. FPNV Positioning Matrix
    • 10.1.1. Quadrants
    • 10.1.2. Business Strategy
    • 10.1.3. Product Satisfaction
  • 10.2. Market Ranking Analysis
  • 10.3. Market Share Analysis
  • 10.4. Competitor SWOT Analysis
  • 10.5. Competitive Scenario
    • 10.5.1. Merger & Acquisition
    • 10.5.2. Agreement, Collaboration, & Partnership
    • 10.5.3. New Product Launch & Enhancement
    • 10.5.4. Investment & Funding
    • 10.5.5. Award, Recognition, & Expansion

11. Company Usability Profiles

  • 11.1. Amgen Inc.
  • 11.2. AstraZeneca PLC
  • 11.3. Bayer AG
  • 11.4. Bristol-Myers Squibb Co
  • 11.5. Carestream Health, Inc.
  • 11.6. Eisai Inc.
  • 11.7. F. Hoffmann-La Roche Ltd
  • 11.8. Fujifilm Corporation
  • 11.9. GE Healthcare Inc.
  • 11.10. GlaxoSmithKline PLC
  • 11.11. Hitachi, Ltd.
  • 11.12. Johnson & Johnson
  • 11.13. Merck & Co. Inc.
  • 11.14. Novartis AG
  • 11.15. Pfizer, Inc.
  • 11.16. Philips Healthcare
  • 11.17. S&P Global Inc.
  • 11.18. Shimadzu Corporation
  • 11.19. Siemens Healthineers AG
  • 11.20. Toshiba Corporation
  • 11.21. Toshiba Medical Systems

12. Appendix

  • 12.1. Discussion Guide
  • 12.2. License & Pricing
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.